These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 35337128)
1. Design, Green Synthesis and Tailoring of Vitamin E TPGS Augmented Niosomal Nano-Carrier of Pyrazolopyrimidines as Potential Anti-Liver and Breast Cancer Agents with Accentuated Oral Bioavailability. Anwer KE; El-Sattar NEAA; Shamaa MM; Zakaria MY; Beshay BY Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337128 [TBL] [Abstract][Full Text] [Related]
2. Experimental design of D-α-tocopherol polyethylene glycol 1000 succinate stabilized bile salt based Nano-vesicles for improved cytotoxicity and bioavailability of colchicine binding site inhibitor Candidates: In Vitro, in silico, and pharmacokinetic studies. Abo Elmaaty A; Al-Karmalawy AA; Nafie MS; Shamaa MM; Zaki I; Alnajjar R; Zakaria MY Int J Pharm; 2023 Jun; 640():122980. PubMed ID: 37116601 [TBL] [Abstract][Full Text] [Related]
3. Design and Synthesis of Newly Synthesized Acrylamide Derivatives as Potential Chemotherapeutic Agents against MCF-7 Breast Cancer Cell Line Lodged on PEGylated Bilosomal Nano-Vesicles for Improving Cytotoxic Activity. Zaki I; Abou-Elkhair RAI; Abu Almaaty AH; A Abu Ali O; Fayad E; Ahmed Gaafar AG; Zakaria MY Pharmaceuticals (Basel); 2021 Oct; 14(10):. PubMed ID: 34681245 [TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
5. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, anticancer, and docking of some S- and/or N-heterocyclic derivatives as VEGFR-2 inhibitors. El-Adl K; Abdel-Rahman AA; Omar AM; Alswah M; Saleh NM Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100237. PubMed ID: 34862655 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
8. "TPGS surface modified bilosomes as boosting cytotoxic oral delivery systems of curcumin against doxorubicin resistant MCF-7 breast cancer cells". Hegazy H; Amin MM; Fayad W; Zakaria MY Int J Pharm; 2022 May; 619():121717. PubMed ID: 35378174 [TBL] [Abstract][Full Text] [Related]
9. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related]
10. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720 [TBL] [Abstract][Full Text] [Related]